The Center for Childhood Infections and Vaccines (CCIV) is addressing major childhood infectious diseases through innovative research into microbial pathogenesis, immune responses in children, and the development of new vaccines and therapeutics.
The center has five integrative focus areas that are designed to build new collaborations, which will lead to sustainable research programs, new grant opportunities and important discoveries. You can learn more about these programs below.
Click "Newsletters & News" in the left menu to learn about the recent happenings of the center.
The full CCIV events calendar is here.
If you would like to use the CCIV logo on your poster, contact Karol Flowers.
The third annual CCIV Symposium was on October 17, 2018. Check out the photos here.
Monday Morning Seminar Series
The Monday Morning Seminar Series will resume in the Fall. The schedule will be announced in early September.
NEW! Aims Review Requests
Are you preparing to submit an application for NIH funding, but need feedback for your aims? Request an Aims Review Session!
Aims Review Sessions are open to CCIV members who are investigators at any level with an upcoming NIH grant submission. Members will be invited to offer review and critque of the Specific Aims sections. The format will be an open 1-hour session with 30 minutes alloted for aims presentation and 30 minutes allotted for friendly and constructive feedback.
Sessions will be held throughout the Summer (June, July, August and September) on the second Monday of each Month. Requests for Aims Review Sessions should be made by the 15th day of the preceding month (where possible) and will be granted on a first-come/first-served basis.
Contact Karol Flowers for more information.
NEW! Research Center Director Opportunity Fund
What is it? The Research Center Director Opportunity Fund is intended to provide modest support for a discrete opportunity that would otherwise be missed without this additional funding. It is intended to provide resources to investigators to remove barriers to research success.
Eligible requests include:
- Supply costs to generate preliminary data to support the submission of a new or revised NIH grant or for experiments requested by reviewers of a submitted manuscript
- Core services related to #1 or #2 above
- Publication fees for pilot grant funded projects
- Travel for study/research purposes
- Other types of requests may be considered on a case-by-case basis
Ineligible requests include:
- Salary/fringe costs to pay for effort
- Travel to conferences
Who is eligible? All faculty with membershp in CCIV.
How do I apply? Submit your written request to the Pediatric Research Alliance Sr. Business Manager, Shantisa Fulgham for review prior to submitting a request to CCIV Center Director, Ann Chahroudi, MD, PhD. The request should be no more than one page and include the following:
- Description of request
- Need justification (including a statement of why funds are not available from other sources)
- Proposed budget
- Attach an "other support" page to the request detailing any funds already received
When are funds awarded? Requests will be reviewed by the CCIV Center Director as received and decisions are anticipated to be made within a week or so.
Atlanta is a leading global center of infectious diseases research, including strengths at Emory University and the Centers for Disease Control and Preventions (CDC). Investigators from a number of additional institutions add to strengths in this area, including Georgia Tech, Morehouse School of Medicine, The University of Georgia, and Medical College of Georgia. Children’s Healthcare of Atlanta will build on these strengths through the CCIV, working with partner institutions in a new enterprise that focuses on microbial pathogenesis, immune responses in children, and the development of new vaccines and therapeutics.
To achieve the overarching goal of impacting child health on a global scale, CCIV will:
- Enhance understanding of infectious diseases, basic immunologic processes, and the development of vaccines and treatments against childhood pathogens.
- Build new collaborations and interdisciplinary projects leading to new extramural funding.
- Develop a program and critical mass of investigators focused on infectious diseases and emerging global health issues. We will integrate efforts within the CCIV with those at the Emory Vaccine Center, Emory Transplant Center, the Carter Center, the Emory Global Health Institute, and CDC initiatives. Participation in CCIV initiatives is open to investigators from these and other research institutions throughout the state of Georgia.
This program includes laboratories focused on basic biology and immunology of the following pathogens:
- Measles virus
- Respiratory syncytial virus (RSV)
- Viral and Bacterial Diarrheal Pathogens
- Structural basis of host-pathogen interactions
The innate immunity program focuses on basic aspects of the immune response to foreign antigens, including the early responses that change the adaptive immune responses. Novel adjuvants (stimulants of the innate response that can enhance vaccine efficacy) are one area of focus of this program.
Vaccine responses in young infants are complicated by an immature immune system and sometimes by the presence of maternal antibody. This program focuses on unique aspects of immunity in the developing fetus and the newborn infant, with the goal of enhancing the efficacy of vaccines given to infants.
The Global Infectious Diseases Program is focused on clinical research and interventions for pathogens that are major causes of childhood mortality in the developing world. Current areas of research by CCIV investigators in this Program include epidemiology and treatment for malaria and rotavirus vaccine efficacy in the developing world.
This program spans the spectrum of the vaccine development process, from the design and testing of new vaccines in the lab to the performance of human clinical trials. The program currently is focusing on vaccines against malaria, rhinovirus, respiratory syncytial virus, HIV/AIDS, Ebola, Zika, and influenza.